Iovance Biotherapeutics, Inc. IOVA Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $196.51M+20.5% | $163.08M+3.1% | $158.13M+19.4% | $132.47M-22.8% | $171.67M+48.4% | ||
| $116.94M-12.7% | $133.9M-6.1% | $142.67M-15.4% | $168.71M-10.3% | $188.05M-9.6% | ||
| $81.76M-0.8% | $82.45M+23.5% | $66.76M+11.4% | $59.94M-15.5% | $70.94M+2.3% | ||
| $58.38M+13.0% | $51.68M-0.1% | $51.71M+3.8% | $49.83M-24.0% | $65.55M+27.2% | ||
| $466.5M+5.4% | $442.69M+3.2% | $429.09M+1.6% | $422.5M-17.6% | $512.65M+12.2% | ||
| $131.39M+0.2% | $131.11M+3.5% | $126.65M+3.4% | $122.47M+9.8% | $111.58M+2.3% | ||
| $269.1M-3.7% | $279.32M-2.1% | $285.21M-3.7% | $296.25M+3.8% | $285.36M+1.0% | ||
| $925.67M+1.4% | $913.17M+0.9% | $904.95M-0.3% | $907.44M-6.1% | $966.74M+6.2% | ||
| $37.45M+69.0% | $22.16M-29.1% | $31.24M-2.4% | $32M+12.3% | $28.49M+3.6% | ||
| $129.42M-6.5% | $138.36M+10.0% | $125.79M-2.6% | $129.16M+5.3% | $122.69M+0.3% | ||
| $74.49M-2.3% | $76.23M-0.8% | $76.88M-3.7% | $79.79M+4.7% | $76.18M-1.9% | ||
| $203.91M-5.0% | $214.59M+5.9% | $202.66M-3.0% | $208.95M+5.1% | $198.88M-0.6% | ||
| $18K+5.9% | $17K+6.3% | $16K+14.3% | $14K0.0% | $14K+7.7% | ||
| -$2.85B-2.8% | -$2.78B-2.7% | -$2.7B-3.5% | -$2.61B-4.5% | -$2.5B-4.9% | ||
| $721.75M+3.3% | $698.58M-0.5% | $702.29M+0.5% | $698.49M-9.0% | $767.87M+8.1% | ||
| $925.67M+1.4% | $913.17M+0.9% | $904.95M-0.3% | $907.44M-6.1% | $966.74M+6.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Iovance Biotherapeutics, Inc.'s total assets?
- Iovance Biotherapeutics, Inc. (IOVA) holds $925.7M in total assets, down 4.3% year over year.
- How much debt does Iovance Biotherapeutics, Inc. have?
- Iovance Biotherapeutics, Inc. carries $46.8M in total debt against $721.8M of shareholders' equity, a debt-to-equity ratio of 0.06.
- How much cash does Iovance Biotherapeutics, Inc. have?
- Iovance Biotherapeutics, Inc. holds $196.5M in cash and equivalents.
- Can Iovance Biotherapeutics, Inc. cover its short-term obligations?
- Its current ratio is 3.60 — current assets exceed current liabilities.
- Where does Iovance Biotherapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
